NCT06642584View on ClinicalTrials.gov

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

July 10, 2025

Study Completion Date

August 13, 2025

Conditions
Healthy Volunteers Type 2 Diabetes
Interventions
DRUG

Semaglutide B

Semaglutide B will be administered subcutaneously.

DRUG

Semaglutide J

Semaglutide J will be administered as oral tablets.

DRUG

Semaglutide L

Semaglutide L will be administered as oral tablets.

DRUG

Semaglutide M

Semaglutide M will be administered as oral tablets.

DRUG

Semaglutide N

Semaglutide N will be administered as oral tablets.

Trial Locations (1)

H3P 3P1

Altasciences, Montreal

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT06642584 - A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV | Biotech Hunter | Biotech Hunter